Zeitschriftenartikel zum Thema „COX-2 selective inhibitor“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "COX-2 selective inhibitor" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
NAKAMURA, Hideo. "Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors." Folia Pharmacologica Japonica 118, no. 3 (2001): 219–30. http://dx.doi.org/10.1254/fpj.118.219.
Der volle Inhalt der QuelleEibl, Guido, Yasunori Takata, Laszlo G. Boros, et al. "Growth Stimulation of COX-2–Negative Pancreatic Cancer by a Selective COX-2 Inhibitor." Cancer Research 65, no. 3 (2005): 982–90. http://dx.doi.org/10.1158/0008-5472.982.65.3.
Der volle Inhalt der Quelle&NA;. "Rofecoxib: a selective COX-2 inhibitor." Drugs & Therapy Perspectives 15, no. 2 (2000): 1–5. http://dx.doi.org/10.2165/00042310-200015020-00001.
Der volle Inhalt der QuelleMartina, Shaunta‘ D., Kimi S. Vesta, and Toni L. Ripley. "Etoricoxib: A Highly Selective COX-2 Inhibitor." Annals of Pharmacotherapy 39, no. 5 (2005): 854–62. http://dx.doi.org/10.1345/aph.1e543.
Der volle Inhalt der QuelleDegraeve, Frédéric, Manlio Bolla, Stéphanie Blaie, et al. "Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells." Journal of Biological Chemistry 276, no. 50 (2001): 46849–55. http://dx.doi.org/10.1074/jbc.m104197200.
Der volle Inhalt der QuelleJeger, Raban V., Jeffrey D. Greenberg, Krishnan Ramanathan, and Michael E. Farkouh. "Lumiracoxib, a highly selective COX-2 inhibitor." Expert Review of Clinical Immunology 1, no. 1 (2005): 37–45. http://dx.doi.org/10.1586/1744666x.1.1.37.
Der volle Inhalt der Quelle&NA;. "Rofecoxib: a selective and effective COX-2 inhibitor." Drugs & Therapy Perspectives 18, no. 2 (2002): 1–3. http://dx.doi.org/10.2165/00042310-200218020-00001.
Der volle Inhalt der QuelleMiller, Jane L. "Second selective COX-2 inhibitor receives marketing approval." American Journal of Health-System Pharmacy 56, no. 13 (1999): 1294. http://dx.doi.org/10.1093/ajhp/56.13.1294a.
Der volle Inhalt der QuelleTakahashi, Toshiyuki, and Mitsuo Miyazawa. "N-Caffeoyl serotonin as selective COX-2 inhibitor." Bioorganic & Medicinal Chemistry Letters 22, no. 7 (2012): 2494–96. http://dx.doi.org/10.1016/j.bmcl.2012.02.002.
Der volle Inhalt der QuelleZhu, Xi-Tian, Lei Chen, and Jian-Hua Lin. "Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty." Medicine 97, no. 31 (2018): e11649. http://dx.doi.org/10.1097/md.0000000000011649.
Der volle Inhalt der QuelleSaito, Takayuki, Ian W. Rodger, Hani Shennib, Fu Hu, Lara Tayara, and Adel Giaid. "Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor." Canadian Journal of Physiology and Pharmacology 81, no. 2 (2003): 114–19. http://dx.doi.org/10.1139/y03-023.
Der volle Inhalt der QuelleÖzdemir, Ahmet, and Halide Edip Temel. "COX inhibitory profiles of a series of thiadiazole-benzothiazole hybrids." European Journal of Life Sciences 3, no. 1 (2024): 9–15. http://dx.doi.org/10.55971/ejls.1443664.
Der volle Inhalt der QuelleOuellet, M., and M. D. Percival. "Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms." Biochemical Journal 306, no. 1 (1995): 247–51. http://dx.doi.org/10.1042/bj3060247.
Der volle Inhalt der QuelleGaytán, M., C. Bellido, C. Morales, J. E. Sánchez-Criado, and F. Gaytán. "Effects of selective inhibition of cyclooxygenase and lipooxygenase pathways in follicle rupture and ovulation in the rat." Reproduction 132, no. 4 (2006): 571–77. http://dx.doi.org/10.1530/rep.1.01236.
Der volle Inhalt der QuelleHong, Ting-Ting, Jinbao Huang, Terrance D. Barrett, and Benedict R. Lucchesi. "Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis." American Journal of Physiology-Heart and Circulatory Physiology 294, no. 1 (2008): H145—H155. http://dx.doi.org/10.1152/ajpheart.00646.2007.
Der volle Inhalt der QuelleClyman, Ronald I., Pierre Hardy, Nahid Waleh, et al. "Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 276, no. 3 (1999): R913—R921. http://dx.doi.org/10.1152/ajpregu.1999.276.3.r913.
Der volle Inhalt der QuelleCharette, L., C. Misquitta, J. Guay, D. Riendeau, and T. R. Jones. "Involvement of cyclooxygenase 2 (COX-2) in intrinsic tone of isolated guinea pig." Canadian Journal of Physiology and Pharmacology 73, no. 11 (1995): 1561–67. http://dx.doi.org/10.1139/y95-215.
Der volle Inhalt der QuelleAltıntop, Mehlika Dilek, Belgin Sever, Halide Edip Temel, Zafer Asım Kaplancıklı, and Ahmet Özdemir. "Design, Synthesis and In vitro COX Inhibitory Profiles of A New Series of Tetrazole-based Hydrazones." European Journal of Life Sciences 1, no. 1 (2022): 20–27. http://dx.doi.org/10.55971/ejls.1095818.
Der volle Inhalt der QuelleRyan, E. P., I. Rahman, and R. P. Phipps. "Cyclooxygenase-2 inhibition induces oxidative stress and decreases intracellular glutathione to reduce survival of human B lymphoma/leukemia cells." Journal of Clinical Oncology 25, no. 18_suppl (2007): 18522. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18522.
Der volle Inhalt der QuelleMysler, E. "Lumiracoxib (Prexige®): a new selective cox-2 inhibitor." International Journal of Clinical Practice 58, no. 6 (2004): 606–11. http://dx.doi.org/10.1111/j.1368-5031.2004.00199.x.
Der volle Inhalt der Quelle&NA;. "Trials supporting selective COX-2 inhibitor safety seriously flawed." Reactions Weekly &NA;, no. 960 (2003): 2. http://dx.doi.org/10.2165/00128415-200309600-00002.
Der volle Inhalt der QuelleDickman, Andrew, and John Ellershaw. "For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?" Palliative Medicine 18, no. 4 (2004): 275–86. http://dx.doi.org/10.1191/0269216304pm894fd.
Der volle Inhalt der QuelleSchiffmann, Susanne, Jessica Sandner, Ronald Schmidt, et al. "The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis." Journal of Lipid Research 50, no. 1 (2008): 32–40. http://dx.doi.org/10.1194/jlr.m800122-jlr200.
Der volle Inhalt der QuelleAntoniou, Katerina, Michael Malamas, and Alexandros A. Drosos. "Clinical pharmacology of celecoxib, a COX-2 selective inhibitor." Expert Opinion on Pharmacotherapy 8, no. 11 (2007): 1719–32. http://dx.doi.org/10.1517/14656566.8.11.1719.
Der volle Inhalt der QuelleDallob, Aimee, Christopher J. Hawkey, Howard Greenberg, et al. "Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor." Journal of Clinical Pharmacology 43, no. 6 (2003): 573–85. http://dx.doi.org/10.1177/0091270003253703.
Der volle Inhalt der QuelleWhitehead, Andrew J., Richard A. Ward, and Martin F. Jones. "Efficient synthesis of the selective COX-2 inhibitor GW406381X." Tetrahedron Letters 48, no. 6 (2007): 911–13. http://dx.doi.org/10.1016/j.tetlet.2006.12.045.
Der volle Inhalt der QuelleJones, Richard A. "Etodolac: An overview of a selective COX-2 inhibitor." Inflammopharmacology 7, no. 3 (1999): 269–75. http://dx.doi.org/10.1007/s10787-999-0010-3.
Der volle Inhalt der QuelleMiyamoto, K. "Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway." Brain 129, no. 8 (2006): 1984–92. http://dx.doi.org/10.1093/brain/awl170.
Der volle Inhalt der QuelleWatson, Douglas J., Sean E. Harper, Peng-Liang Zhao, Hui Quan, James A. Bolognese, and Thomas J. Simon. "Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis." Archives of Internal Medicine 160, no. 19 (2000): 2998. http://dx.doi.org/10.1001/archinte.160.19.2998.
Der volle Inhalt der QuelleSharma, Rajesh, Jitendra Sainy, and Subhash Chaturvedi. "2-Amino-5-sulfanyl-1,3,4-thiadiazoles: A new series of selective cyclooxygenase-2 inhibitors." Acta Pharmaceutica 58, no. 3 (2008): 317–26. http://dx.doi.org/10.2478/v10007-008-0011-6.
Der volle Inhalt der QuelleGurgel, Bruno César de Vasconcelos, Fernanda Vieira Ribeiro, Marco Antônio Dias da Silva, et al. "Selective COX-2 inhibitor reduces bone healing in bone defects." Brazilian Oral Research 19, no. 4 (2005): 312–16. http://dx.doi.org/10.1590/s1806-83242005000400014.
Der volle Inhalt der QuelleSchlemper, Valfredo, and João B. Calixto. "Mechanisms underlying the contraction induced by bradykinin in the guinea pig epithelium-denuded trachea." Canadian Journal of Physiology and Pharmacology 80, no. 4 (2002): 360–67. http://dx.doi.org/10.1139/y02-061.
Der volle Inhalt der QuelleMenozzi, Alessandro, Cristina Pozzoli, Enzo Poli, Lucia Tagliaferri, Giuseppe Placenza, and Simone Bertini. "Effects of nonselective and selective cyclooxygenase inhibitors on the contractions of isolated bronchial smooth muscle in the horse." Acta Veterinaria Brno 87, no. 2 (2018): 99–107. http://dx.doi.org/10.2754/avb201887020099.
Der volle Inhalt der QuelleKim, Min Ji, Hwi-Ho Lee, Choi Kim, et al. "Selective mPGES-1 Inhibitor Ameliorated Adjuvant-Induced Arthritis in the Rat Model." Journal of Chemistry 2024 (February 13, 2024): 1–8. http://dx.doi.org/10.1155/2024/5531519.
Der volle Inhalt der QuelleYamamoto, Tatsuo, and Natsuko Nozaki-Taguchi. "Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor." Brain Research 739, no. 1-2 (1996): 104–10. http://dx.doi.org/10.1016/s0006-8993(96)00817-7.
Der volle Inhalt der QuellePatrignani, Paola, Marta L. Capone, and Stefania Tacconelli. "Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor." Expert Opinion on Pharmacotherapy 4, no. 2 (2003): 265–84. http://dx.doi.org/10.1517/eoph.4.2.265.21085.
Der volle Inhalt der QuelleTian, Feng, Lin Wang, and Ya-Jie Zhang. "Selective COX-2 inhibitor celecoxib inhibits liver fibrogenesis in rats." World Chinese Journal of Digestology 19, no. 19 (2011): 2002. http://dx.doi.org/10.11569/wcjd.v19.i19.2002.
Der volle Inhalt der QuelleGrobelny, Pawel, Arijit Mukherjee, and Gautam R. Desiraju. "Polymorphs and hydrates of Etoricoxib, a selective COX-2 inhibitor." CrystEngComm 14, no. 18 (2012): 5785. http://dx.doi.org/10.1039/c2ce06604a.
Der volle Inhalt der QuelleMyoung, Hoon. "Anti-Cancer Effects of a Selective Cox-2 Inhibitor, Celecoxib." Journal of Oral and Maxillofacial Surgery 65, no. 9 (2007): 35.e3–35.e4. http://dx.doi.org/10.1016/j.joms.2007.06.608.
Der volle Inhalt der QuelleSchattenkirchner, Manfred. "Meloxicam:a selective COX-2 inhibitor non-steroidal anti-inflammatory drug." Expert Opinion on Investigational Drugs 6, no. 3 (1997): 321–34. http://dx.doi.org/10.1517/13543784.6.3.321.
Der volle Inhalt der QuelleTALHARI, C., I. LAUCEVICIUTE, E. ENDERLEIN, T. RUZICKA, and B. HOMEY. "COX-2–selective inhibitor valdecoxib induces severe allergic skin reactions." Journal of Allergy and Clinical Immunology 115, no. 5 (2005): 1089–90. http://dx.doi.org/10.1016/j.jaci.2004.12.1135.
Der volle Inhalt der QuelleXu, Xiangbo, Xihua Chen, Yunfeng Li та ін. "Cyclooxygenase-2 Regulated by the Nuclear Factor-κB Pathway Plays an Important Role in Endometrial Breakdown in a Female Mouse Menstrual-like Model". Endocrinology 154, № 8 (2013): 2900–2911. http://dx.doi.org/10.1210/en.2012-1993.
Der volle Inhalt der QuelleEL-Shazly, Amany, Amal EL-Gohary, Laila EL-Shazly, and Ghada EL-Hossary. "Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits." Acta Pharmaceutica 58, no. 2 (2008): 163–73. http://dx.doi.org/10.2478/v10007-008-0009-0.
Der volle Inhalt der QuelleAssali, Mohyeddin, Murad Abualhasan, Hadeel Sawaftah, Mohammed Hawash, and Ahmed Mousa. "Synthesis, Biological Activity, and Molecular Modeling Studies of Pyrazole and Triazole Derivatives as Selective COX-2 Inhibitors." Journal of Chemistry 2020 (March 24, 2020): 1–14. http://dx.doi.org/10.1155/2020/6393428.
Der volle Inhalt der QuelleFarzaneh, Shabnam, Elnaz Zeinalzadeh, Bahram Daraei, Soraya Shahhosseini, and Afshin Zarghi. "New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity." Anti-Cancer Agents in Medicinal Chemistry 18, no. 2 (2018): 295–301. http://dx.doi.org/10.2174/1871520617666171003145533.
Der volle Inhalt der QuelleBlack, W. C., C. Bayly, M. Belley, et al. "From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors." Bioorganic & Medicinal Chemistry Letters 6, no. 6 (1996): 725–30. http://dx.doi.org/10.1016/0960-894x(96)00100-x.
Der volle Inhalt der QuelleGariepy, Helaine, Jun Zhao, and Dan Levy. "Differential contribution of COX-1 and COX-2 derived prostanoids to cortical spreading depression—Evoked cerebral oligemia." Journal of Cerebral Blood Flow & Metabolism 37, no. 3 (2016): 1060–68. http://dx.doi.org/10.1177/0271678x16650217.
Der volle Inhalt der QuelleHaq, Kautsar Ul, Nur Lailatus Sa'adah, Imam Siswanto, and Hery Suwito. "Bioactivity of dihydropyrimidinone derivatives as inhibitors of cyclooxygenase-2 (COX-2): an in silico approach." RSC Advances 13, no. 49 (2023): 34348–57. http://dx.doi.org/10.1039/d3ra05942a.
Der volle Inhalt der QuelleLongo, Walter E., Brian Erickson, Ninder Panesar, John E. Mazuski, Sandra Robinson, and Donald L. Kaminski. "The role of selective cyclooxygenase isoforms in human intestinal smooth muscle cell stimulated prostanoid formation and proliferation." Mediators of Inflammation 7, no. 6 (1998): 373–80. http://dx.doi.org/10.1080/09629359890749.
Der volle Inhalt der QuelleMiladiyah, Isnatin, Jumina Jumina, Sofia Mubarika Haryana, and Mustofa Mustofa. "IN SILICO MOLECULAR DOCKING OF XANTHONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITOR AGENTS." International Journal of Pharmacy and Pharmaceutical Sciences 9, no. 3 (2017): 98. http://dx.doi.org/10.22159/ijpps.2017v9i3.15382.
Der volle Inhalt der Quelle